Resibufogenin Prevents the Manifestations of Preeclampsia in an Animal Model of the Syndrome
Resibufogenin Prevents the Manifestations of Preeclampsia in an Animal Model of the Syndrome
复制标题
DOI：
10.3109/10641950802629709
复制
发表时间：
2010-02
影响因子：
1.5
通讯作者：
D. Horvat;J. Severson;M. Uddin;B. Mitchell;J. Puschett
中科院分区：
文献类型：
--
作者：
D. Horvat;J. Severson;M. Uddin;B. Mitchell;J. Puschett
背景和目标。我们已经开发了一种先兆子痫的大鼠模型，该模型基于过度的体积扩张，包括高血压、蛋白尿和子宫内生长受限。在该模型中，Na +/ K+ ATP酶的循环类固醇抑制剂海蟾毒配基的尿排泄在高血压和蛋白尿发生之前增加。海蟾毒配基的类似物脂蟾毒配基成功地治疗高血压和蛋白尿。方法.在该模型中，我们在妊娠早期给予脂蟾毒配基，在综合征发生之前。结果我们发现脂蟾毒配基不仅可以预防高血压和蛋白尿的发生，还可以预防胎儿宫内生长受限的发生。讨论这些结果可能与人类状况有关。
Background and Objectives. We have developed a rat model of preeclampsia which is based upon excessive volume expansion and includes hypertension, proteinuria and intrauterine growth restriction. In this model, the urinary excretion of the circulating steroid inhibitor of Na +/ K+ ATPase, marinobufagenin, is increased prior to the development of hypertension and proteinuria. An analogue of marinobufagenin, resibufogenin, successfully treats the hypertension and proteinuria. Methods. We administered resibufogenin early in pregnancy in this model, prior to the development of the syndrome. Results. We found that resibufogenin not only prevented the advent of hypertension and proteinuria, but also the development of intrauterine growth restriction. Discussion. These results may have relevance to the human condition.